Novartis data highlight benefit of early treatment initiation in patients with secondary progressive multiple sclerosis (SPMS)

Novartis announced Thursday that Mayzent data from the Phase III EXPAND trial were published in the European Journal of Neurology after the 6^th EAN, held virtually due to COVID-19. These data, which included separate post hoc analyses from the Phase III EXPAND trial, continue to build on existing clinical evidence that Mayzent has significant impact on reducing the risk of disease progression, including physical disability and cognitive decline for patients with SPMS.

Novartis highlighted that long-term efficacy data from EXPAND, previously presented at the American Association of Neurology Congress, show patients with SPMS continuously treated with Mayzent (siponimod) experienced a sustained effect in delaying disability for up to 5 years, demonstrating the advantages of early treatment.

“We are pleased to highlight data demonstrating that Mayzent helps slow disability progression and declining cognitive function,” said Norman Putzki, M.D., Global Head of Development Neuroscience. “For people living with MS, it’s essential to get ahead of disease progression and treat early so that they can maintain as much independence as possible in the future. We are dedicated to reimagining MS treatment and bringing hope to people with progressive diseases like MS.”